



**Figure 5a**



## Figure 5b




**Chrysomycin A**

Chrysomycin A was identified as a hit in a highthroughput screen against multi-drug-resistant tuberculosis strains

A 10-step scalable synthesis of chrysomycin A was developed, which also afforded the synthesis of 33 new analogues


(+)-64, representing one of the new analogues, exhibited 5-fold stronger activity against multi-drug-resistant tuberculosis strains



**(+)-64**

Wu F, Zhang J, Song F, Wang S, Guo H, Wei Q, Dai H, Chen X, Xia X, Liu X, Zhang L, Yu JQ, Lei X. Chrysomycin A Derivatives for the Treatment of Multi-Drug-Resistant Tuberculosis. ACS Cent Sci. 2020 Jun 24;6(6):928-938. doi: 10.1021/acscentsci.0c00122. Epub 2020 May 4. PMID: 32607440; PMCID: PMC7318084.

# Figure 5c




Arylomycin A-C<sub>16</sub>

Arylomycins represent a class of NP antibiotics with weak activity and limited spectrum

Chemical derivatization of arylomycin A-C<sub>16</sub> led to the discovery of G0775, which had more potent, broad-spectrum activity against Gram-negative bacteria


G0775 exhibits unprecedented molecular mechanism of action and activity against multidrug-resistant Gram-negative clinical isolates in vitro and in vivo



G0775

Smith, P.A., Koehler, M.F.T., Girgis, H.S. et al. Optimized arylomycins are a new class of Gram-negative antibiotics. *Nature* 561, 189–194 (2018). <https://doi.org/10.1038/s41586-018-0483-6>

# Figure 5d




**Bleomycin A2  
(BLM A2)**

*Streptomyces mobaraensis*  
DSM40847 is identified by  
genome mining as a new  
bleomycin producer

Targeted manipulation of the  
biosynthetic pathway of  
bleomycin in *S. mobaraensis* led  
to the production of 6'-deoxy-  
BLM A2

6'-deoxy-BLM A2 exhibited more  
rapid DNA cleavage than  
bleomycin A2



**6'-deoxy-Bleomycin A2  
(6'-deoxy-BLM A2)**

Hindra, Yang D, Teng Q, Dong LB, Crnovčić I, Huang T, Ge H, Shen B. Genome Mining of *Streptomyces mobaraensis* DSM40847 as a Bleomycin Producer Providing a Biotechnology Platform To Engineer Designer Bleomycin Analogues. *Org Lett.* 2017 Mar 17;19(6):1386-1389. doi: 10.1021/acs.orglett.7b00283.